

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC. 20231 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/827,345	04/06/2001	Jean-Claude Chermann	065691-0216	4575
7:	590 08/14/2002			
Stephen B. Maebius			EXAMINER	
FOLEY & LARDNER Washington Harbour			HILL, MYRON G	
3000 K Street, N.W., Suite 500 Washington, DC 20007-5109			ART UNIT	PAPER NUMBER
Washington, D	C 20007-3109		1648	12
			DATE MAILED: 08/14/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)			
		09/827,345	CHERMANN ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Myron G. Hill	1648			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM						
THE N - Extens after S - If the p - If NO - Failure	PRTENED STATUTORY PERIOD FOR REPLIALING DATE OF THIS COMMUNICATION. Sions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. Deriod for reply specified above is less than thirty (30) days, a repperiod for reply is specified above, the maximum statutory period is to reply within the set or extended period for reply will, by statutiply received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	I36(a). In no event, however, may a re- ly within the statutory minimum of thirty will apply and will expire SIX (6) MON'	ply be timely filed  (30) days will be considered timely.  THS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).			
1)⊠	Responsive to communication(s) filed on 06	<u> April 2001</u> .				
2a) <u></u> □		his action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
•	on of Claims					
	Claim(s) 1-25 is/are pending in the application is the application is the application in the application in the application is the application in the application in the application is the application in the application in the application is the application in the application in the application is the application in the application in the application is the application in the application is the application in					
	4a) Of the above claim(s) is/are withdra	awn from consideration.				
5) Claim(s) is/are allowed.						
·	6) Claim(s) is/are rejected.					
	Claim(s) is/are objected to.	ltion requirement				
	Claim(s) 1-25 are subject to restriction and/o	or election requirement.				
	on Papers	nor				
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
44)□	Applicant may not request that any objection to	is: a) ☐ approved b) ☐	disapproved by the Examiner.			
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
Priority	Acknowledgment is made of a claim for fore	ian priority under 35 U.S.C.	§ 119(a)-(d) or (f).			
1		g., p.,,				
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.						
	Certified copies of the priority documents have been received in Application No  2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachme						
1) Not	ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(	5) Notice of	v Summary (PTO-413) Paper No(s)  of Informal Patent Application (PTO-152) .			

Application/Control Number: 09/827,345

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1- 12, drawn to a peptide vaccine composition, classified in class 424, subclass 204.1.
- IF Applicant elects Group I, then they must also elect one inventive sequence from SEQ ID#s 1- 22.
- Claims 13- 21, drawn to a DNA vaccine, classified in class 514, subclass
   44.
- IF Applicant elects Group II, then they must also elect one inventive DNA sequence that encodes SEQ ID#s 1- 22.
- III. Claim22- 23, drawn to an antibody, classified in class 530, subclass 387.1.
- IV. Claims 24- 25, drawn to a diagnostic method for patients who do not progress, classified in class 435, subclass 5.

Therefore, if group I or II is chosen, election is required of one of inventions I-II and one of inventive sequences SEQ ID #1- 22 or DNA encoding SEQ ID #1- 22.

The inventions are distinct, each from the other because of the following reasons:

Inventions SEQ ID #1- 22 or DNA encoding SEQ ID #1- 22 are unrelated.

Inventions are unrelated if it can be shown that they are not disclosed as capable of use

Application/Control Number: 09/827,345

Art Unit: 1648

Page 3

together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different polypeptides and polynucleotides. Therefore, where structural identity is required, such as for hybridization or expression or methods of treatment, the different sequences have different effects.

Inventions I- III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to distinct chemical structures that have different functions.

Inventions I- III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions (I- III) are not required to practice IV.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and they have search requirements that are not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1648

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 703-308-4521. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4247. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

MARY E MOSHER PRIMARY EXAMINER GROUP 1809

1600

Page 4

Myron G. Hill Patent Examiner August 12, 2002